Literature DB >> 12567160

Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease.

Madhavi Thomas1, Wei Dong Le, Joseph Jankovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12567160     DOI： 10.1097/00002826-200301000-00005

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  14 in total

1.  A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.

Authors:  Hyo Jin Son; Ji Ae Lee; Nari Shin; Ji Hyun Choi; Jai Woong Seo; Dae Yoon Chi; Cheol Soon Lee; Eun-Mee Kim; Han Choe; Onyou Hwang
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures.

Authors:  Jayne Abraham; Patrick D Fox; Carlo Condello; Alyssa Bartolini; Sookyong Koh
Journal:  Neurobiol Dis       Date:  2012-02-16       Impact factor: 5.996

3.  Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion.

Authors:  Christine Fox; Andra Dingman; Nikita Derugin; Michael F Wendland; Catherine Manabat; Shaoquan Ji; Donna M Ferriero; Zinaida S Vexler
Journal:  J Cereb Blood Flow Metab       Date:  2005-09       Impact factor: 6.200

4.  Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.

Authors:  Robert DiCenzo; Derick R Peterson; Kim Cruttenden; Peter Mariuz; Naser L Rezk; Jill Hochreiter; Harris Gelbard; Giovanni Schifitto
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

Review 5.  Traumatic injury to the immature brain: inflammation, oxidative injury, and iron-mediated damage as potential therapeutic targets.

Authors:  Mathew B Potts; Seong-Eun Koh; William D Whetstone; Breset A Walker; Tomoko Yoneyama; Catherine P Claus; Hovhannes M Manvelyan; Linda J Noble-Haeusslein
Journal:  NeuroRx       Date:  2006-04

6.  Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3.

Authors:  Yuri Cho; Hyo Jin Son; Eun-Mee Kim; Ji Hyun Choi; Sung Tae Kim; In Jung Ji; Dong Hee Choi; Tong H Joh; Yoon Seong Kim; Onyou Hwang
Journal:  Neurotox Res       Date:  2009-07-07       Impact factor: 3.911

7.  Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease.

Authors:  Rita Costa; Elena Speretta; Damian C Crowther; Isabel Cardoso
Journal:  J Biol Chem       Date:  2011-10-13       Impact factor: 5.157

Review 8.  The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment.

Authors:  Janice E Clements; Joseph L Mankowski; Lucio Gama; M Christine Zink
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

Review 9.  Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease.

Authors:  Sushruta Koppula; Hemant Kumar; In Su Kim; Dong-Kug Choi
Journal:  Mediators Inflamm       Date:  2012-04-22       Impact factor: 4.711

10.  Doxycycline increases neurogenesis and reduces microglia in the adult hippocampus.

Authors:  Sebastien Sultan; Elias Gebara; Nicolas Toni
Journal:  Front Neurosci       Date:  2013-07-25       Impact factor: 4.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.